Vehicle selection for water-insoluble research compounds

The problem with the default

Most non-steroidal SARMs and several of the nootropic compounds discussed on this site are practically insoluble in water. The standard solution is a concentrated DMSO stock diluted into aqueous buffer at the point of use, and it works — but DMSO is not an inert carrier and treating it as one introduces errors that look like pharmacology.

DMSO affects membrane fluidity, induces differentiation in some cell lines, alters cytochrome P450 activity and has measurable effects on neuronal electrophysiology at concentrations well below those that reduce viability. A vehicle control at the matched final concentration is not a formality; it is the only way to separate compound effect from solvent effect.

Keeping the final concentration honest

Below 0.1% final DMSO is the usual target for cell culture, and below 0.05% for sensitive primary preparations and electrophysiology. Meeting that target means the stock must be concentrated enough that the dilution factor does the work.

This creates the central tension: a stock concentrated enough to keep the vehicle low is also concentrated enough that the compound may crash out on dilution. A compound that precipitates on entering aqueous buffer is present at its solubility limit, not at the concentration on the calculation, and every point above that limit on a dose-response curve is the same dose.

This is the most common silent failure in in-vitro work with insoluble compounds. It produces a curve that plateaus for reasons that have nothing to do with receptor saturation.

Checking for precipitation properly

Visual inspection against a dark background catches gross precipitation but not fine or slow crystallisation. Where the endpoint matters, confirm solubility at the working concentration by nephelometry, by filtering and quantifying the filtrate, or at minimum by inspecting under magnification after the incubation period rather than only at preparation.

Precipitation is time-dependent. A solution that is clear at preparation may be cloudy after four hours at 37 °C, which means the exposure your cells received is not the exposure you designed.

Alternatives worth considering

Cyclodextrins — hydroxypropyl-beta-cyclodextrin in particular — form inclusion complexes with hydrophobic molecules and can carry compounds into aqueous media at concentrations DMSO cannot reach, without DMSO's biological activity. They are not inert either, and they can sequester lipophilic components of the medium.

Ethanol suits some compounds and carries its own well-known effects. Lipid vehicles, suspensions and oil formulations are standard for in-vivo work with compounds such as aniracetam, where the vehicle materially determines exposure.

For in-vivo work the vehicle is a study variable, not a detail. A suspension that settles between animals delivers different doses to the first and last, and agitation immediately before each withdrawal is the difference between a reproducible dose and an unknown one.

What to report

State the vehicle, the final vehicle concentration, the stock concentration and the confirmed solubility limit in the methods. Readers cannot evaluate a dose-response curve without knowing whether the top of the range was actually in solution, and a paper that omits this is asking to be taken on trust.

References and authoritative sources

Chemical identity, regulatory status and anti-doping classification should be confirmed against primary sources rather than against this page. The records below are the ones to check first.

1. PubChem compound record (US National Library of Medicine)
2. PubMed indexed literature

These are database and regulatory sources. Citations to specific primary papers are being added to this page as part of ongoing scientific review; until they appear, treat the mechanism and literature sections above as a summary to verify rather than a citation of record.